Vanguard Capital Management Discloses New 5.17% Passive Stake in PTC Therapeutics Inc (PTCT)

On April 30, 2026, Vanguard Capital Management LLC filed a Schedule 13G with the SEC, disclosing a new 5.17% passive ownership stake in PTC Therapeutics Inc (PTCT). The filing indicates that as of March 31, 2026, the investment adviser beneficially owns 4,284,448 shares of common stock. Within this position, Vanguard reported sole voting power over 608,192 shares and sole dispositive power over the full 4,284,448 shares. The filing includes securities deemed to be beneficially owned by several Vanguard affiliates, including Vanguard Asset Management Limited and Vanguard Global Advisers, LLC. This acquisition represents a significant increase from a previous 0% holding, crossing the 5% regulatory threshold. The filing was made under Rule 13d-1(b), certifying that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. No other single person's interest in these securities exceeds 5% of the total shares outstanding.